Multidrug resistance-associated protein 3 plays an important role in protection against acute toxicity of diclofenac

Drug Metabolism and Disposition

Volumn 43, Issue 7, 2015, Pages 944-950

  Scialis, Renato J ^a   Csanaky, Iván L ^b   Goedken, Michael J ^c   Manautou, José E ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG GLUCURONIDATION; IN VIVO STUDY; INTESTINE INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SMALL INTESTINE; ANIMAL; BILE; C57BL MOUSE; CHEMICALLY INDUCED; ENTEROPATHY; GENETICS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIVER; METABOLISM; PATHOLOGY; PEPTIC ULCER;

MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BILE; DICLOFENAC; GLUCURONIDES; IMMUNOHISTOCHEMISTRY; INTESTINAL DISEASES; INTESTINE, SMALL; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-GLYCOPROTEINS; PEPTIC ULCER;

EID: 84940381642     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.061705     Document Type: Article

References (48)

1. Altschul SF, Wootton JC, Gertz E.M., Agarwala R., Morgulis A, Schäffer AA, and Yu YK (2005) Protein database searches using compositionally adjusted substitution matrices. FEBS J 272: 5101-5109.
2. Atchison CR, West AB, Balakumaran A, Hargus S.J., Pohl LR, Daiker DH, Aronson JF, Hoffmann W.E., Shipp BK, and Treinen-Moslen M (2000) Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats. Gastroenterology 119:1537-1547.
3. Blazka ME, Wilmer JL, Holladay S.D., Wilson RE, and Luster MI (1995) Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 133:43-52.
4. Cheng X, Maher J, Chen C., and Klaassen CD (2005) Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). Drug Metab Dispos 33:1062-1073.
5. Daly AK, Aithal GP, Leathart J.B., Swainsbury RA, Dang TS, and Day CP (2007) Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132:272-281.
6. de Abajo F.J., Montero D, Madurga M., and García Rodríguez LA (2004) Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 58:71-80.
7. Depomed (2009) Cambia (diclofenac potassium for oral solution) prescribing information. Newark, CA
8. Drozdzik M, Gröer C, Penski J., Lapczuk J, Ostrowski M, Lai Y., Prasad B, Unadkat JD, Siegmund W, and Oswald S (2014) Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. Mol Pharm 11:3547-3555.
9. Ebner T, Heinzel G, Prox A., Beschke K, and Wachsmuth H (1999) Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos 27:1143-1149.
10. Fukushima-Uesaka H., Saito Y, Maekawa K., Hasegawa R, Suzuki K, Yanagawa T., Kajio H, Kuzuya N, Noda M., and Yasuda K, et al. (2007) Genetic variations of the ABC transporter gene ABCC3 in a Japanese population. Drug Metab Pharmacokinet 22:129-135.
11. Gómez-Lechón MJ, Ponsoda X, O'Connor E, Donato T, Castell JV, and Jover R (2003) Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS. Biochem Pharmacol 66:2155-2167.
12. Hargus SJ, Martin BM, George J.W., and Pohl LR (1995) Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 8:993-996.
13. Hickey EJ, Raje RR, Reid V.E., Gross SM, and Ray SD (2001) Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. Free Radic Biol Med 31:139-152.
14. Huang L, Berry L, Ganga S., Janosky B, Chen A, Roberts J., Colletti AE, and Lin MH (2010) Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab Dispos 38:223-231.
15. Ishiguro N, Maeda K, Saito A., Kishimoto W, Matsushima S, Ebner T., Roth W, Igarashi T, and Sugiyama Y (2008) Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 36:796-805.
16. Kenny JR, Maggs JL, Meng X, Sinnott D., Clarke SE, Park BK, and Stachulski AV (2004) Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac. J Med Chem 47:2816-2825.
17. King C, Tang W, Ngui J., Tephly T, and Braun M (2001) Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 61:49-53.
18. Kobayashi K, Ito K, Takada T., Sugiyama Y, and Suzuki H (2008) Functional analysis of non-synonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3. Pharmacogenet Genomics 18:823-833.
19. Kretz-Rommel A and Boelsterli UA (1993) Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol Appl Pharmacol 120:155-161.
20. Krieglstein CF, Anthoni C, Cerwinka W.H., Stokes KY, Russell J, Grisham MB, and Granger DN (2007) Role of blood- and tissue-associated inducible nitric-oxide synthase in colonic inflammation. Am J Pathol 170:490-496.
21. Lagas JS, Sparidans RW, Wagenaar E, Beijnen J.H., and Schinkel AH (2010) Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 77:687-694.
22. Lagas JS, van der Kruijssen CM, van de Wetering K, Beijnen JH, and Schinkel AH (2009) Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benz-bromarone. Drug Metab Dispos 37:129-136.
23. Lang T, Hitzl M, Burk O., Mornhinweg E, Keil A, Kerb R., Klein K, Zanger UM, Eichelbaum M, and Fromm MF (2004) Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 14:155-164.
24. Lim MS, Lim PL, Gupta R, and Boelsterli UA (2006) Critical role of free cytosolic calcium, but not uncoupling, in mitochondrial permeability transition and cell death induced by diclofenac oxidative metabolites in immortalized human hepatocytes. Toxicol Appl Pharmacol 217: 322-331.
25. Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M., Borst P, and Elferink RO (2005) Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42:1091-1098.
26. Manautou JE, Hoivik DJ, Tveit A, Hart S.G., Khairallah EA, and Cohen SD (1994) Clofibrate pretreatment diminishes acetaminophen's selective covalent binding and hepatotoxicity. Toxicol Appl Pharmacol 129:252-263.
27. McNeely W and Goa KL (1999) Diclofenac-potassium in migraine: a review. Drugs 57: 991-1003.
28. Menassé R, Hedwall PR, Kraetz J, Pericin C, Riesterer L, Sallmann A, Ziel R, and Jaques R (1978) Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol Suppl 22:5-16.
29. Moolenbeek C and Ruitenberg EJ (1981) The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim 15:57-59.
30. Novartis (2011) Voltaren (diclofenac sodium enteric-coated tablets) prescribing information. East Hanover, NJ
31. Ramirez-Alcantara V., LoGuidice A, and Boelsterli UA (2009) Protection from diclofenac-induced small intestinal injury by the JNK inhibitor SP600125 in a mouse model of NSAID-associated enteropathy. Am J Physiol Gastrointest Liver Physiol 297:G990-G998.
32. Riess W, Stierlin H, Degen P., Faigle JW, Gérardin A, Moppert J., Sallmann A, Schmid K, Schweizer A., and Sulc M, et al. (1978) Pharmacokinetics and metabolism of the antiinflammatory agent Voltaren. Scand J Rheumatol Suppl 22:17-29.
33. Sallustio BC and Holbrook FL (2001) In vivo perturbation of rat hepatocyte canalicular membrane function by diclofenac. Drug Metab Dispos 29:1535-1538.
34. Sallustio BC, Sabordo L, Evans A.M., and Nation RL (2000) Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr Drug Metab 1:163-180.
35. Sarda S, Page C, Pickup K., Schulz-Utermoehl T, and Wilson I (2012) Diclofenac metabolism in the mouse: novel in vivo metabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometry. Xenobiotica 42:179-194.
36. Seitz S and Boelsterli UA (1998) Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 115:1476-1482.
37. Seitz S, Kretz-Rommel A, Oude Elferink RP, and Boelsterli UA (1998) Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 11:513-519.
38. Sekine S, Ito K, and Horie T (2006) Oxidative stress and Mrp2 internalization. Free Radic Biol Med 40:2166-2174.
39. Tang W, Stearns RA, Bandiera S.M., Zhang Y., Raab C, Braun MP, Dean D.C., Pang J., Leung KH, and Doss GA, et al. (1999) Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos 27:365-372.
40. Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, and Brouwer KL (2008) Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos 36:911-915.
41. Trelle S, Reichenbach S, Wandel S., Hildebrand P, Tschannen B, Villiger P.M., Egger M., and Jüni P (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network metaanalysis. BMJ 342:c7086.
42. Vlaming ML, van Esch A, Pala Z, Wagenaar E., van de Wetering K, van Tellingen O, and Schinkel AH (2009) Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 8:3350-3359.
43. Wallace JL (2008) Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 88:1547-1565.
44. Willis JV, Kendall MJ, Flinn R.M., Thornhill DP, and Welling PG (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 16: 405-410.
45. Zamek-Gliszczynski M.J., Nezasa K, Tian X., Bridges AS, Lee K, Belinsky MG, Kruh G.D., and Brouwer KL (2006) Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. J Pharmacol Exp Ther 319:1485-1491.
46. Zelcer N, Saeki T, Bot I., Kuil A, and Borst P (2003) Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J 369:23-30.
47. Zelcer N, Saeki T, Reid G., Beijnen JH, and Borst P (2001) Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276:46400-46407.
48. Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall HU, Wielinga PR, Kuil A, Kunne C, Smith A, and van der Valk M, et al. (2006) Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 44: 768-775.